{"id":44011,"date":"2019-02-13T19:09:10","date_gmt":"2019-02-13T17:09:10","guid":{"rendered":"https:\/\/blog.cofb.cat\/?p=44011"},"modified":"2019-02-13T19:09:10","modified_gmt":"2019-02-13T17:09:10","slug":"opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria","status":"publish","type":"post","link":"https:\/\/www.cofb.org\/ca\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/","title":{"rendered":"Opioides majors, atenci\u00f3 farmac\u00e8utica i PMM: Tercera sessi\u00f3 del cicle de confer\u00e8ncies sobre reducci\u00f3 de riscos en la farm\u00e0cia comunit\u00e0ria"},"content":{"rendered":"<p><strong>Opioides majors, atenci\u00f3 farmac\u00e8utica i Programa de manteniment amb metadona (PMM).<\/strong> Aquest va ser el t\u00edtol de la tercera sessi\u00f3 celebrada al Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) sobre el <strong>cicle de confer\u00e8ncies de reducci\u00f3 de danys a la farm\u00e0cia comunit\u00e0ria <\/strong>en qu\u00e8 -a trav\u00e9s de les intervencions de Jos\u00e9 P\u00e9rez de los Cobos, de la Unitat de Conductes Addictives de l&#8217;Hospital de la Santa Creu i Sant Pau i Juliana Salazar, del Servei de Gen\u00e8tica del mateix hospital- van abordar els aspectes seg\u00fcents:<\/p>\n<ul>\n<li><strong>Actualitzaci\u00f3 en farmacologia<\/strong> dels opioides majors<\/li>\n<li><strong>Farmacologia i farmacogen\u00e8tica<\/strong> dels opioides<\/li>\n<li><strong>Recepta electr\u00f2nica, farmacogen\u00e8tica i PRM<\/strong> (problemes relacionats amb el medicament) en el <strong>PMM <\/strong>(programa de manteniment amb metadona).<\/li>\n<\/ul>\n<figure id=\"attachment_44190\" aria-describedby=\"caption-attachment-44190\" style=\"width: 620px\" class=\"wp-caption aligncenter\"><a href=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2019\/02\/cofb.190205-22.jpg\"><img fetchpriority=\"high\" decoding=\"async\" class=\"wp-image-44190 size-large\" title=\"Un moment de la sessi\u00f3 &quot;Opioides majors, atenci\u00f3 farmac\u00e8utica i Programa de manteniment amb metadona (PMM)&quot;.\" src=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2019\/02\/cofb.190205-22-1024x683.jpg\" alt=\"Un moment de la sessi\u00f3 &quot;Opioides majors, atenci\u00f3 farmac\u00e8utica i Programa de manteniment amb metadona (PMM)&quot;.\" width=\"620\" height=\"414\" \/><\/a><figcaption id=\"caption-attachment-44190\" class=\"wp-caption-text\">Un moment de la sessi\u00f3 &#8220;Opioides majors, atenci\u00f3 farmac\u00e8utica i Programa de manteniment amb metadona (PMM)&#8221;.<\/figcaption><\/figure>\n<h1><strong><span style=\"color: #008080;\">El Programa de Manteniment amb Metadona, un dels 3 \u00e0mbits principals de la reducci\u00f3 de riscos<\/span><\/strong><\/h1>\n<p>A l&#8217;inici de la sessi\u00f3, Guillermo Bagaria, responsable d&#8217;Atenci\u00f3 Farmac\u00e8utica del COFB va recordar que &#8220;<strong>el Programa de Manteniment amb Metadona esdev\u00e9 una de les 3 potes principals de l&#8217;actuaci\u00f3 de les farm\u00e0cies en la reducci\u00f3 de riscos en l&#8217;\u00e0mbit de les drogodepend\u00e8ncies <\/strong>(juntament amb la <strong>Prova r\u00e0pida del VIH<\/strong> i el <strong>Programa d&#8217;Intercanvi de Xeringues (PIX)<\/strong>&#8220;. &#8220;La idea de la sessi\u00f3 \u00e9s <strong>comprendre d&#8217;una forma m\u00e9s \u00e0mplia<\/strong> la <strong>gesti\u00f3 de la metadona i dels opioides<\/strong>. La xerrada no nom\u00e9s est\u00e0 destinada als farmac\u00e8utics comunitaris i als estudiants d&#8217;\u00faltim curs de Farm\u00e0cia, sin\u00f3 que tamb\u00e9 l&#8217;hem volgut fer extensiva als professionals dels Centres d\u2019atenci\u00f3 i seguiment a les drogodepend\u00e8ncies (CAS) que treballen amb la <strong>deshabituaci\u00f3 d&#8217;opioides<\/strong> i que presten un servei en moltes ocasions sin\u00e8rgic amb les farm\u00e0cies dels municipis&#8221;.<\/p>\n<h1><span style=\"color: #008080;\"><strong>Opioides majors, atenci\u00f3 farmac\u00e8utica i Programa de Manteniment amb Metadona<\/strong><\/span><\/h1>\n<p>Jos\u00e9 P\u00e9rez de los Cobos va exposar les subst\u00e0ncies consumides per hero\u00efn\u00f2mans (hero\u00efna i altres subst\u00e0ncies com alcohol, benzodiacepines, c\u00e0nnabis, coca\u00efna&#8230;), coca\u00efn\u00f2mans (coca\u00efna i altres, per\u00f2 no hero\u00efna) i alcoh\u00f2lics (alcohol i altres per\u00f2 no coca\u00efna o hero\u00efna).<\/p>\n<p>I va destacar que <strong>les subst\u00e0ncies susceptibles d&#8217;ab\u00fas activen el sistema de recompensa cerebral la qual cosa provoca plaer, refor\u00e7 del comportament (repetici\u00f3) i producci\u00f3 de records<\/strong>. Les <strong>etapes de la intoxicaci\u00f3<\/strong> que va descriure el Dr. P\u00e9rez de los Cobos s\u00f3n les seg\u00fcents: intoxicaci\u00f3 i <em>binges<\/em> (efectes aguts), abstin\u00e8ncia i emocionalitat negativa i preocupaci\u00f3 i anticipaci\u00f3.<\/p>\n<p>El doctor tamb\u00e9 va fer refer\u00e8ncia a la <strong>definici\u00f3 del s\u00edndrome de depend\u00e8ncia<\/strong> segons la CIE-10 (Clasificaci\u00f3n Estad\u00edstica Internacional de Enfermedades y Problemas Relacionados con la Salud): &#8220;Un patr\u00f3 de fen\u00f2mens fisiol\u00f2gics, comportamentals i cognitius en qu\u00e8 el consum d&#8217;una droga o tipus de drogues adquireix una prioritat m\u00e9s alta per un individu que qualsevol altre tipus dels comportaments que van tenir en el passat un valor m\u00e9s elevat. La manifestaci\u00f3 caracter\u00edstica de la s\u00edndrome de depend\u00e8ncia \u00e9s el desig (sovint fort i a vegades insuperable) d&#8217;ingerir drogues&#8221;. Finalment, va centrar-se en el perfil farmacodin\u00e0mic dels opioides i en les bases farmacodin\u00e0miques dels programes de manteniment.<\/p>\n<figure id=\"attachment_44191\" aria-describedby=\"caption-attachment-44191\" style=\"width: 620px\" class=\"wp-caption aligncenter\"><a href=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2019\/02\/cofb.190205-05.jpg\"><img decoding=\"async\" class=\"wp-image-44191 size-large\" title=\"D'esquerra a dreta: Javier P\u00e9rez de los Cobos, Guillermo Bagaria i Juliana Salazar.\" src=\"https:\/\/blog.cofb.cat\/wp-content\/uploads\/2019\/02\/cofb.190205-05-1024x683.jpg\" alt=\"D'esquerra a dreta: Javier P\u00e9rez de los Cobos, Guillermo Bagaria i Juliana Salazar.\" width=\"620\" height=\"414\" \/><\/a><figcaption id=\"caption-attachment-44191\" class=\"wp-caption-text\">D&#8217;esquerra a dreta: Javier P\u00e9rez de los Cobos, Guillermo Bagaria i Juliana Salazar.<\/figcaption><\/figure>\n<h1><span style=\"color: #008080;\"><strong>La farmacogen\u00e8tica del tractament amb metadona<\/strong><\/span><\/h1>\n<p>La doctora Juliana Salazar va exposar, com a conclusions de la\u00a0 la seva intervenci\u00f3 que:<\/p>\n<ul>\n<li><strong>El tractament de manteniment amb metadona \u00e9s efica\u00e7 i segur<\/strong>, malgrat que hi ha una elevada variabilitat interindividual, resposta i\/o toxicitat, explicada en part per la variabilitat de gens implicats en la farmacocin\u00e8tica i la farmacodin\u00e0mica del f\u00e0rmac (CYP2B6, CYP2D6 i ABCB1).<\/li>\n<li>La <strong>R-metadona<\/strong> seria la responsable de l&#8217;<strong>efecte terap\u00e8utic<\/strong> i la <strong>S-metadona<\/strong> de la <strong>toxicitat associada al f\u00e0rmac<\/strong>.<\/li>\n<li>A m\u00e9s de considerar l&#8217;efecte de les variants gen\u00e8tiques s&#8217;ha de considerar la co-medicaci\u00f3 que afecta, especialment, la <strong>farmacocin\u00e8tica de la metadona<\/strong>.<\/li>\n<\/ul>\n<div class=\"box success\">\n<h2><span style=\"color: #008080;\"><strong>Pr\u00f2ximes confer\u00e8ncies del cicle de reducci\u00f3 de riscos en la farm\u00e0cia comunit\u00e0ria<\/strong><\/span><\/h2>\n<p>Al llarg del<strong> 2019<\/strong>, encara queden per celebrar-se\u00a0<strong>dues confer\u00e8ncies m\u00e9s d&#8217;aquest cicle<\/strong>, totes elles relacionades amb diferents aspectes de la reducci\u00f3 de riscos i danys a la farm\u00e0cia comunit\u00e0ria.<\/p>\n<ul>\n<li><strong>PIX, PMM, VIH: experi\u00e8ncies, casos pr\u00e0ctics i gesti\u00f3 de conflictes. (5\/3\/2019)<\/strong>.\u00a0<em>Inscripcions\u00a0<strong><a href=\"http:\/\/www.cofb.org\/web\/guest\/cursos?p_p_id=portletllistatactivitats_WAR_portletllistatactivitats_INSTANCE_Au9v&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_col_id=column-2&amp;p_p_col_pos=1&amp;p_p_col_count=2&amp;_portletllistatactivitats_WAR_portletllistatactivitats_INSTANCE_Au9v_strutsAction=%2Fview%2Fdetall&amp;_portletllistatactivitats_WAR_portletllistatactivitats_INSTANCE_Au9v_id=2558\" target=\"_blank\" rel=\"noopener\">aqu\u00ed<\/a><\/strong><\/em><\/li>\n<li><strong>Subst\u00e0ncies d\u2019ab\u00fas: OMA Consum de l\u2019alcohol i drogues a l\u2019adolesc\u00e8ncia. (9\/4\/2019)<\/strong>.\u00a0<em>Inscripcions\u00a0<strong><a href=\"http:\/\/www.cofb.org\/web\/guest\/cursos?p_p_id=portletllistatactivitats_WAR_portletllistatactivitats_INSTANCE_Au9v&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_col_id=column-2&amp;p_p_col_pos=1&amp;p_p_col_count=2&amp;_portletllistatactivitats_WAR_portletllistatactivitats_INSTANCE_Au9v_strutsAction=%2Fview%2Fdetall&amp;_portletllistatactivitats_WAR_portletllistatactivitats_INSTANCE_Au9v_id=2559\" target=\"_blank\" rel=\"noopener\">aqu\u00ed<\/a>\u00a0<\/strong><\/em><\/div><\/li>\n<\/ul>\n<h1><span style=\"color: #008080;\"><strong>Bona acollida entre els assistents<br \/>\n<\/strong><\/span><\/h1>\n<p>Guillermo Bagaria, responsable d&#8217;Atenci\u00f3 Farmac\u00e8utica del COFB, va destacar que la xerrada va tenir una <strong>&#8220;molt bona acollida&#8221; <\/strong>i que <strong>&#8220;la convocat\u00f2ria es va fer extensiva a psiquiatres dels\u00a0 Centres d\u2019atenci\u00f3 i seguiment a les drogodepend\u00e8ncies (CAS) <\/strong>de la prov\u00edncia de Barcelona.<strong> Per aix\u00f2, entre els assistents hi havia una representaci\u00f3 tant de metges com de farmac\u00e8utics que ofereixen el Programa de Manteniment amb Metadona&#8221;<\/strong>.<\/p>\n<p>I va afegir: &#8220;Amb les pon\u00e8ncies del Dr. Jos\u00e9 P\u00e9rez de los Cobos i la Dra. Juliana Salazar, de l&#8217;Hospital de Sant Pau, van quedar paleses les <strong>dificultats en l&#8217;adequaci\u00f3 de dosis<\/strong> per la gran variabilitat gen\u00e8tica i ambiental que afecta aspectes <strong>farmacodin\u00e0mics<\/strong> i <strong>farmacocin\u00e8tics<\/strong>&#8220;. Per \u00faltim, Bagaria va exposar que durant la sessi\u00f3 &#8220;tamb\u00e9 es van traslladar les <strong>moltes interaccions<\/strong> que tenen els <strong>opioides majors<\/strong> amb <strong>medicaci\u00f3 concomitant<\/strong> i l&#8217;<strong>opacitat de la informaci\u00f3<\/strong> <strong>que t\u00e9 l&#8217;actual sistema d&#8217;ordre m\u00e8dica<\/strong> del Programa de manteniment amb metadona en contraposici\u00f3 <strong>amb els avantatges que suposar\u00e0 la seva incorporaci\u00f3 a la recepta electr\u00f2nica<\/strong>&#8220;.<\/p>\n<p><strong>Altres publicacions d&#8217;inter\u00e8s:<\/strong><\/p>\n<ul>\n<li><a href=\"https:\/\/blog.cofb.cat\/pautes-consum-dheroina-cocaina-catalunya-atencio-farmaceutica-contrarestar-danys-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/\" target=\"_blank\" rel=\"noopener\">Pautes de consum d\u2019hero\u00efna i coca\u00efna a Catalunya i atenci\u00f3 farmac\u00e8utica per contrarestar els danys [Cicle de confer\u00e8ncies sobre reducci\u00f3 de riscos en la farm\u00e0cia comunit\u00e0ria] (Gener 2019)<\/a><\/li>\n<li><a href=\"https:\/\/blog.cofb.cat\/us-terapeutic-cannabis-comenca-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/\" target=\"_blank\" rel=\"noopener\">\u00das terap\u00e8utic del c\u00e0nnabis. Comen\u00e7a el cicle de confer\u00e8ncies sobre reducci\u00f3 de riscos en la farm\u00e0cia comunit\u00e0ria (Gener 2019)<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Opioides majors, atenci\u00f3 farmac\u00e8utica i Programa de manteniment amb metadona (PMM). Aquest va ser el t\u00edtol de la tercera sessi\u00f3 celebrada al Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) sobre el cicle de confer\u00e8ncies de reducci\u00f3 de danys a la farm\u00e0cia comunit\u00e0ria en qu\u00e8 -a trav\u00e9s de les intervencions de Jos\u00e9 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":44190,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[57],"tags":[393,3373,18,19,143,145,53,68,69,2832,2979,3427,2981,2982,3402,3403,3404,396],"class_list":["post-44011","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mon-collegial","tag-cannabis","tag-cicle-de-conferencies-sobre-reduccio-de-riscos-en-la-farmacia-comunitaria","tag-cofb","tag-collegi-de-farmaceutics-de-barcelona","tag-consum-de-drogues","tag-drogues","tag-farmaceutics","tag-farmacia","tag-farmacia-comunitaria","tag-opioides","tag-pix","tag-pmm","tag-programa-dintercanvi-de-xeringues","tag-programa-de-manteniment-amb-metadona","tag-programes-de-reduccio-de-riscos","tag-reduccio-de-danys","tag-reduccio-de-riscos","tag-us-terapeutic-del-cannabis"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Opioides majors, atenci\u00f3 farmac\u00e8utica i PMM: Tercera sessi\u00f3 del cicle de confer\u00e8ncies sobre reducci\u00f3 de riscos en la farm\u00e0cia comunit\u00e0ria - Col\u00b7legi de Farmac\u00e8utics de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Opioides majors, atenci\u00f3 farmac\u00e8utica i PMM: Tercera sessi\u00f3 del cicle de confer\u00e8ncies sobre reducci\u00f3 de riscos en la farm\u00e0cia comunit\u00e0ria - Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Opioides majors, atenci\u00f3 farmac\u00e8utica i Programa de manteniment amb metadona (PMM). Aquest va ser el t\u00edtol de la tercera sessi\u00f3 celebrada al Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) sobre el cicle de confer\u00e8ncies de reducci\u00f3 de danys a la farm\u00e0cia comunit\u00e0ria en qu\u00e8 -a trav\u00e9s de les intervencions de Jos\u00e9 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/\" \/>\n<meta property=\"og:site_name\" content=\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-02-13T17:09:10+00:00\" \/>\n<meta name=\"author\" content=\"wpAdminCofbOrg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:site\" content=\"@farmaceuticsbcn\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"wpAdminCofbOrg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/\"},\"author\":{\"name\":\"wpAdminCofbOrg\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\"},\"headline\":\"Opioides majors, atenci\u00f3 farmac\u00e8utica i PMM: Tercera sessi\u00f3 del cicle de confer\u00e8ncies sobre reducci\u00f3 de riscos en la farm\u00e0cia comunit\u00e0ria\",\"datePublished\":\"2019-02-13T17:09:10+00:00\",\"dateModified\":\"2019-02-13T17:09:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/\"},\"wordCount\":1068,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/#primaryimage\"},\"thumbnailUrl\":\"\",\"keywords\":[\"c\u00e0nnabis\",\"Cicle de confer\u00e8ncies sobre reducci\u00f3 de riscos en la farm\u00e0cia comunit\u00e0ria\",\"COFB\",\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"consum de drogues\",\"drogues\",\"farmac\u00e8utics\",\"Farm\u00e0cia\",\"farm\u00e0cia comunit\u00e0ria\",\"opioides\",\"PIX\",\"PMM\",\"Programa d'Intercanvi de Xeringues\",\"programa de manteniment amb metadona\",\"Programes de reducci\u00f3 de riscos\",\"reducci\u00f3 de danys\",\"reducci\u00f3 de riscos\",\"\u00das terap\u00e8utic del c\u00e0nnabis\"],\"articleSection\":[\"M\u00f3n col\u00b7legial\"],\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/\",\"url\":\"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/\",\"name\":\"Opioides majors, atenci\u00f3 farmac\u00e8utica i PMM: Tercera sessi\u00f3 del cicle de confer\u00e8ncies sobre reducci\u00f3 de riscos en la farm\u00e0cia comunit\u00e0ria - Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"isPartOf\":{\"@id\":\"https:\/\/www.cofb.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2019-02-13T17:09:10+00:00\",\"dateModified\":\"2019-02-13T17:09:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inici\",\"item\":\"https:\/\/novaorg.cofb.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Opioides majors, atenci\u00f3 farmac\u00e8utica i PMM: Tercera sessi\u00f3 del cicle de confer\u00e8ncies sobre reducci\u00f3 de riscos en la farm\u00e0cia comunit\u00e0ria\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cofb.org\/#website\",\"url\":\"https:\/\/www.cofb.org\/\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cofb.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cofb.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cofb.org\/#organization\",\"name\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\",\"url\":\"https:\/\/www.cofb.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"contentUrl\":\"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png\",\"width\":500,\"height\":105,\"caption\":\"Col\u00b7legi de Farmac\u00e8utics de Barcelona\"},\"image\":{\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/farmaceuticsbcn\/\",\"https:\/\/twitter.com\/farmaceuticsbcn\",\"https:\/\/www.instagram.com\/farmaceuticsbcn\/\",\"https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb\",\"name\":\"wpAdminCofbOrg\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/www.cofb.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g\",\"caption\":\"wpAdminCofbOrg\"},\"sameAs\":[\"http:\/\/192.168.64.122\/wordpress\"],\"url\":\"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Opioides majors, atenci\u00f3 farmac\u00e8utica i PMM: Tercera sessi\u00f3 del cicle de confer\u00e8ncies sobre reducci\u00f3 de riscos en la farm\u00e0cia comunit\u00e0ria - Col\u00b7legi de Farmac\u00e8utics de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/","og_locale":"ca_ES","og_type":"article","og_title":"Opioides majors, atenci\u00f3 farmac\u00e8utica i PMM: Tercera sessi\u00f3 del cicle de confer\u00e8ncies sobre reducci\u00f3 de riscos en la farm\u00e0cia comunit\u00e0ria - Col\u00b7legi de Farmac\u00e8utics de Barcelona","og_description":"Opioides majors, atenci\u00f3 farmac\u00e8utica i Programa de manteniment amb metadona (PMM). Aquest va ser el t\u00edtol de la tercera sessi\u00f3 celebrada al Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) sobre el cicle de confer\u00e8ncies de reducci\u00f3 de danys a la farm\u00e0cia comunit\u00e0ria en qu\u00e8 -a trav\u00e9s de les intervencions de Jos\u00e9 [&hellip;]","og_url":"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/","og_site_name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","article_publisher":"https:\/\/www.facebook.com\/farmaceuticsbcn\/","article_published_time":"2019-02-13T17:09:10+00:00","author":"wpAdminCofbOrg","twitter_card":"summary_large_image","twitter_creator":"@farmaceuticsbcn","twitter_site":"@farmaceuticsbcn","twitter_misc":{"Escrit per":"wpAdminCofbOrg","Temps estimat de lectura":"5 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/#article","isPartOf":{"@id":"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/"},"author":{"name":"wpAdminCofbOrg","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb"},"headline":"Opioides majors, atenci\u00f3 farmac\u00e8utica i PMM: Tercera sessi\u00f3 del cicle de confer\u00e8ncies sobre reducci\u00f3 de riscos en la farm\u00e0cia comunit\u00e0ria","datePublished":"2019-02-13T17:09:10+00:00","dateModified":"2019-02-13T17:09:10+00:00","mainEntityOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/"},"wordCount":1068,"commentCount":0,"publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/#primaryimage"},"thumbnailUrl":"","keywords":["c\u00e0nnabis","Cicle de confer\u00e8ncies sobre reducci\u00f3 de riscos en la farm\u00e0cia comunit\u00e0ria","COFB","Col\u00b7legi de Farmac\u00e8utics de Barcelona","consum de drogues","drogues","farmac\u00e8utics","Farm\u00e0cia","farm\u00e0cia comunit\u00e0ria","opioides","PIX","PMM","Programa d'Intercanvi de Xeringues","programa de manteniment amb metadona","Programes de reducci\u00f3 de riscos","reducci\u00f3 de danys","reducci\u00f3 de riscos","\u00das terap\u00e8utic del c\u00e0nnabis"],"articleSection":["M\u00f3n col\u00b7legial"],"inLanguage":"ca","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/","url":"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/","name":"Opioides majors, atenci\u00f3 farmac\u00e8utica i PMM: Tercera sessi\u00f3 del cicle de confer\u00e8ncies sobre reducci\u00f3 de riscos en la farm\u00e0cia comunit\u00e0ria - Col\u00b7legi de Farmac\u00e8utics de Barcelona","isPartOf":{"@id":"https:\/\/www.cofb.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/#primaryimage"},"image":{"@id":"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/#primaryimage"},"thumbnailUrl":"","datePublished":"2019-02-13T17:09:10+00:00","dateModified":"2019-02-13T17:09:10+00:00","breadcrumb":{"@id":"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/novaorg.cofb.net\/2019\/02\/13\/opioides-majors-atencio-farmaceutica-pmm-tercera-sessio-cicle-conferencies-sobre-reduccio-riscos-farmacia-comunitaria\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inici","item":"https:\/\/novaorg.cofb.net\/"},{"@type":"ListItem","position":2,"name":"Opioides majors, atenci\u00f3 farmac\u00e8utica i PMM: Tercera sessi\u00f3 del cicle de confer\u00e8ncies sobre reducci\u00f3 de riscos en la farm\u00e0cia comunit\u00e0ria"}]},{"@type":"WebSite","@id":"https:\/\/www.cofb.org\/#website","url":"https:\/\/www.cofb.org\/","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","description":"","publisher":{"@id":"https:\/\/www.cofb.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cofb.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/www.cofb.org\/#organization","name":"Col\u00b7legi de Farmac\u00e8utics de Barcelona","url":"https:\/\/www.cofb.org\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","contentUrl":"https:\/\/www.cofb.org\/wp-content\/uploads\/2023\/11\/cropped-Logotip-COFB.png","width":500,"height":105,"caption":"Col\u00b7legi de Farmac\u00e8utics de Barcelona"},"image":{"@id":"https:\/\/www.cofb.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/farmaceuticsbcn\/","https:\/\/twitter.com\/farmaceuticsbcn","https:\/\/www.instagram.com\/farmaceuticsbcn\/","https:\/\/www.linkedin.com\/company\/farmaceuticsbcn\/"]},{"@type":"Person","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/22ed7eea88da74b0fa4d3154ad87ffcb","name":"wpAdminCofbOrg","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/www.cofb.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1721b20b3b8ca882c3b56ec6c978c594fff670e40c0718e9190eaeeb76aae7d8?s=96&d=mm&r=g","caption":"wpAdminCofbOrg"},"sameAs":["http:\/\/192.168.64.122\/wordpress"],"url":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"wpAdminCofbOrg","author_link":"https:\/\/www.cofb.org\/ca\/author\/wpadmincofborg\/"},"uagb_comment_info":0,"uagb_excerpt":"Opioides majors, atenci\u00f3 farmac\u00e8utica i Programa de manteniment amb metadona (PMM). Aquest va ser el t\u00edtol de la tercera sessi\u00f3 celebrada al Col\u00b7legi de Farmac\u00e8utics de Barcelona (COFB) sobre el cicle de confer\u00e8ncies de reducci\u00f3 de danys a la farm\u00e0cia comunit\u00e0ria en qu\u00e8 -a trav\u00e9s de les intervencions de Jos\u00e9 [&hellip;]","_links":{"self":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/44011","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/comments?post=44011"}],"version-history":[{"count":0,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/posts\/44011\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/media?parent=44011"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/categories?post=44011"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cofb.org\/ca\/wp-json\/wp\/v2\/tags?post=44011"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}